Synergy CHC Corp. (SNYR) - 10-Q Summary
Business Context and Reporting Period
Company: Synergy CHC Corp.
Reporting Period: Quarter and nine months ended September 30, 2024 (Unaudited)
Business Overview: A consumer health care company focused on building a portfolio of brands, primarily FOCUSfactor (brain health) and Flat Tummy (weight management). The company operates as a single segment with sales primarily in the United States and Canada.
Recent Corporate Action: A 1-for-11.9 reverse stock split was effected on September 11, 2024. All share data is retroactively adjusted.
Key Financial Metrics (Nine Months Ended Sept 30, 2024)
| Metric | 2024 (9 Months) | 2023 (9 Months) |
|---|---|---|
| Revenue | $24,563,036 | $29,559,440 |
| Gross Profit | $17,141,106 | $21,207,795 |
| Gross Margin | 70% | 72% |
| Net Income | $2,019,309 | $3,747,444 |
| Net Income Per Share (Basic/Diluted) | $0.27 | $0.50 |
| Operating Cash Flow | ($1,377,479) | ($2,737,849) |
| Cash & Restricted Cash | $359,375 | $732,534 |
| Total Debt (Current + Long-term) | $32,000,533 | $27,618,132 |
| Working Capital | ($6,395,684) | ($2,199,033) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 17% year-over-year to $24.6M. Management attributes this to a delay in a significant shipment of FOCUSfactor supplements due to a packaging upgrade in Q3 2024 and the cessation of consumer goods sales.
- Profitability: Net income decreased 46% to $2.0M, driven primarily by lower revenue volumes. Gross margin compressed slightly from 72% to 70%.
- Expense Management: Selling and marketing expenses decreased 13% to $9.1M, and General and Administrative expenses decreased 20% to $3.4M, reflecting improved cost management.
- Debt Restructuring: In June 2024, the company consolidated multiple related-party loans (Knight Therapeutics) into a single agreement extending maturity to March 31, 2026. This reduced the effective interest rate, lowering interest expense slightly despite higher principal balances.
- Liquidity: Cash on hand decreased from $632k to $259k. The company maintains a working capital deficit of $6.4M.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management previously noted substantial doubt regarding the company's ability to continue as a going concern due to accumulated deficits and working capital shortages. However, management concluded that recent debt restructuring, net income generation, and the successful completion of an IPO (see below) alleviates these doubts for the next 12 months.
- Subsequent Event (IPO): On October 24, 2024, the company completed an Initial Public Offering, selling 1,150,000 shares at $9.00 per share. Net proceeds were approximately $8.4 million. This capital raise is expected to significantly improve liquidity.
- Debt Covenants: The consolidated related-party loan requires the company to raise $5 million in equity by March 31, 2025. Failure to do so triggers a $1 million fee and a default event. The loan also requires a minimum quarterly EBITDA of $1.25M and FocusFactor trailing 12-month net sales of $30M.
- Customer Concentration: High concentration risk exists; two customers accounted for 69% of revenue in the first nine months of 2024.
- Legal Proceedings: Significant litigation with a contract manufacturer (Atrium Innovations) was settled in December 2023, resulting in a $2.2M gain (reduction of cost of sales) and a new $5.45M loan payable. Another lawsuit (LODC Group) was settled in April 2024.
Investor Verification Checklist
- IPO Proceeds Utilization: Verify how the $8.4M in net IPO proceeds (closed Oct 2024) is being deployed to address the $6.4M working capital deficit and upcoming debt maturities.
- Debt Covenant Compliance: Confirm the company meets the $1.25M quarterly EBITDA and $30M trailing sales covenants to avoid default on the Knight Therapeutics loan.
- Revenue Recovery: Assess whether the packaging upgrade delays have been resolved and if Q4 2024 revenue shows a rebound to pre-2023 levels.
- Related Party Transactions: Review the terms of the consolidated $12.3M related-party debt and the $2.9M short-term related-party note to understand the total exposure to the CEO and Knight Therapeutics.
- Customer Diversification: Evaluate the risk associated with 69% of revenue coming from just two customers and the stability of those relationships.